AstraZeneca’s asthma drug Fasenra looks promising for a set of rare chronic immune diseases
Just 16 months after the FDA approved AstraZeneca’s Fasenra for a severe form of asthma, investigators at the NIH have found that the drug appears to hold great promise for treating rare chronic immune disorders called hypereosinophilic syndromes, or HES.
The team led by Amy Klion, chief of the Human Eosinophil Section in the NIAID Laboratory of Parasitic Disease, followed a familiar path with this drug, which has already proved its ability to flag eosinophils for destruction, warranting the approval in the fall of 2017 for severe asthma associated with eosinophils in the lungs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
